• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PCSK9 基因敲除小鼠对血管周围颈动脉套环放置引起的新生内膜形成具有保护作用。

PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement.

机构信息

Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padua, Italy.

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.

出版信息

Atherosclerosis. 2016 Oct;253:214-224. doi: 10.1016/j.atherosclerosis.2016.07.910. Epub 2016 Jul 22.

DOI:10.1016/j.atherosclerosis.2016.07.910
PMID:27477186
Abstract

BACKGROUND AND AIMS

Proprotein convertase subtilisin kexin type 9 (PCSK9) induces degradation of the low-density lipoprotein-receptor (LDLR). Smooth muscle cells (SMCs) in human atherosclerotic plaques and cultured SMCs express PCSK9. The present study aimed at defining the role of PCSK9 on vascular response to injury.

METHODS

Carotid neointimal lesions were induced by positioning a non-occlusive collar in PCSK9 knock-out (PCSK9) and wild type littermate (PCSK9) mice.

RESULTS

In PCSK9 mice, we observed a significantly less intimal thickening (p < 0.05), a lower intimal media ratio (p < 0.02), and a tendency to higher lumen area, compared to PCSK9 mice. When compared with PCSK9, lesions of PCSK9 mice had a higher content of SMCs (p < 0.05) and collagen (p < 0.05), while no difference was observed in the accumulation of macrophages. PCSK9 was detectable in both left and right carotids artery in regions occupied by medial and neointimal SMCs. SMCs freshly isolated from PCSK9, when compared to PCSK9 cells, showed higher levels of α-smooth muscle actin (α-SMA; 2.24 ± 0.36 fold; p < 0.01) and myosin heavy chain II (MHC-II; 8.65 ± 1.55 fold; p < 0.01), and lower levels of caldesmon mRNA(-54 ± 14%; p < 0.01). PCSK9 cells also showed a slower proliferation rate, and an impaired migratory capacity and G1/S progression of the cell cycle. The reconstitution of PCSK9 expression, by retroviral infection of PCSK9 SMCs, led to a downregulation of α-SMA (-56 ± 2%; p < 0.01), MHC-II (-45% ± 25.5 fold: p = 0.06) and calponin (-25% ± 0.8 fold: p < 0.05) and induction of caldesmon mRNA (1.46 ± 0.3 fold; p < 0.05). Proliferation rate of SMCs PCSK9 was significantly lower compared to PCSK9 reconstituted cells.

CONCLUSIONS

Taken together, the present results suggest that PCSK9, by sustaining SMC synthetic phenotype, proliferation, and migration, may play a pro-atherogenic role in the arterial wall.

摘要

背景与目的

前蛋白转化酶枯草溶菌素 9(PCSK9)诱导低密度脂蛋白受体(LDLR)降解。人动脉粥样硬化斑块中的平滑肌细胞(SMCs)和培养的 SMCs 表达 PCSK9。本研究旨在定义 PCSK9 在血管损伤反应中的作用。

方法

通过在 PCSK9 敲除(PCSK9)和野生型同窝仔(PCSK9)小鼠中定位非闭塞颈圈来诱导颈动脉内膜新生病变。

结果

与 PCSK9 相比,PCSK9 小鼠的内膜增厚明显减少(p<0.05),内膜中膜比降低(p<0.02),管腔面积有增高趋势。与 PCSK9 相比,PCSK9 小鼠的病变中 SMCs 含量较高(p<0.05),胶原含量较高(p<0.05),而巨噬细胞的积累无差异。在左、右颈动脉中,PCSK9 存在于由中膜和内膜 SMCs 占据的区域。与 PCSK9 细胞相比,从 PCSK9 中分离的 SMCs 显示出更高水平的α-平滑肌肌动蛋白(α-SMA;2.24±0.36 倍;p<0.01)和肌球蛋白重链 II(MHC-II;8.65±1.55 倍;p<0.01),以及更低水平的钙调蛋白 mRNA(-54±14%;p<0.01)。PCSK9 细胞的增殖速度较慢,迁移能力受损,细胞周期的 G1/S 进展受损。通过逆转录病毒感染 PCSK9 SMCs 重建 PCSK9 表达,导致α-SMA 下调(-56±2%;p<0.01),MHC-II 下调(-45%±25.5 倍:p=0.06),钙调蛋白下调(-25%±0.8 倍:p<0.05)和钙调蛋白 mRNA 诱导(1.46±0.3 倍;p<0.05)。与 PCSK9 重建细胞相比,PCSK9 SMCs 的增殖率显著降低。

结论

综上所述,本研究结果表明,PCSK9 通过维持 SMC 合成表型、增殖和迁移,可能在动脉壁中发挥促动脉粥样硬化作用。

相似文献

1
PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement.PCSK9 基因敲除小鼠对血管周围颈动脉套环放置引起的新生内膜形成具有保护作用。
Atherosclerosis. 2016 Oct;253:214-224. doi: 10.1016/j.atherosclerosis.2016.07.910. Epub 2016 Jul 22.
2
Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation.考替司他丁抑制人血管平滑肌细胞的迁移和增殖,并减少颈动脉结扎后的新生内膜形成。
Circ Res. 2013 May 24;112(11):1444-55. doi: 10.1161/CIRCRESAHA.112.300695. Epub 2013 Apr 17.
3
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease.PCSK9(前蛋白转化酶枯草溶菌素 9)触发血管平滑肌细胞衰老和凋亡:其在退行性血管疾病中直接作用的意义。
Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):67-86. doi: 10.1161/ATVBAHA.121.316902. Epub 2021 Nov 23.
4
Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice.β3整合素介导小鼠颈动脉结扎后新生内膜中平滑肌细胞的积聚。
Circulation. 2004 Mar 30;109(12):1564-9. doi: 10.1161/01.CIR.0000121733.68724.FF. Epub 2004 Mar 8.
5
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.培养的平滑肌细胞分泌的前蛋白转化酶枯草溶菌素 9(PCSK9)降低巨噬细胞 LDLR 水平。
Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026. Epub 2011 Nov 25.
6
PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin.PCSK9 诱导大鼠平滑肌细胞增殖并拮抗辛伐他汀的多效作用。
Int J Mol Sci. 2021 Apr 16;22(8):4114. doi: 10.3390/ijms22084114.
7
Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation.血小板反应蛋白-1激活小鼠颈动脉结扎后的中层平滑肌细胞并触发新生内膜形成。
Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2163-9. doi: 10.1161/ATVBAHA.107.151282. Epub 2007 Aug 30.
8
Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia.环磷酸腺苷磷酸二酯酶1C信号在调节生长因子受体稳定性、血管平滑肌细胞生长、迁移和内膜增生中的作用。
Circ Res. 2015 Mar 27;116(7):1120-32. doi: 10.1161/CIRCRESAHA.116.304408. Epub 2015 Jan 21.
9
The Actin-Binding Protein Drebrin Inhibits Neointimal Hyperplasia.肌动蛋白结合蛋白 drebrin 抑制内膜增生。
Arterioscler Thromb Vasc Biol. 2016 May;36(5):984-93. doi: 10.1161/ATVBAHA.115.306140. Epub 2016 Mar 24.
10
Inhibition of Smooth Muscle β-Catenin Hinders Neointima Formation After Vascular Injury.抑制平滑肌β-连环蛋白可阻碍血管损伤后的新生内膜形成。
Arterioscler Thromb Vasc Biol. 2017 May;37(5):879-888. doi: 10.1161/ATVBAHA.116.308643. Epub 2017 Mar 16.

引用本文的文献

1
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.依洛尤单抗在自身免疫性或炎性疾病中强化降低低密度脂蛋白胆固醇水平:FOURIER试验分析
Circulation. 2025 May 20;151(20):1467-1476. doi: 10.1161/CIRCULATIONAHA.124.072756. Epub 2025 Apr 21.
2
PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose.血管平滑肌细胞中前蛋白转化酶枯草溶菌素9的表达:胰岛素抵抗和高糖的作用
Int J Mol Sci. 2025 Jan 24;26(3):1003. doi: 10.3390/ijms26031003.
3
Assessing the impact of evolocumab on thin-cap fibroatheroma and endothelial function in patients with very high-risk atherosclerotic cardiovascular disease: a study protocol for a randomized controlled trial.
评估阿利西尤单抗对极高风险动脉粥样硬化性心血管疾病患者薄帽纤维粥样斑块和内皮功能的影响:一项随机对照试验的研究方案
Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1236-1246. doi: 10.21037/cdt-24-336. Epub 2024 Dec 19.
4
PCSK9 and Coronary Artery Plaque-New Opportunity or Red Herring?PCSK9 与冠状动脉斑块——新机遇还是无稽之谈?
Curr Atheroscler Rep. 2024 Oct;26(10):589-602. doi: 10.1007/s11883-024-01230-6. Epub 2024 Aug 16.
5
The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol.载脂蛋白 C-III 在心力衰竭和其他心血管疾病中的作用:除了对 LDL 胆固醇的影响之外的作用机制。
Heart Fail Rev. 2024 Sep;29(5):917-937. doi: 10.1007/s10741-024-10409-7. Epub 2024 Jun 18.
6
Atherosclerosis and Toll-Like Receptor4 (TLR4), Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1), and Proprotein Convertase Subtilisin/Kexin Type9 (PCSK9).动脉粥样硬化与 Toll 样受体 4(TLR4)、凝集素样氧化型低密度脂蛋白-1(LOX-1)和前蛋白转化酶枯草溶菌素 9(PCSK9)。
Mediators Inflamm. 2024 Feb 27;2024:5830491. doi: 10.1155/2024/5830491. eCollection 2024.
7
Maternal Obesity Modulates Cord Blood Concentrations of Proprotein Convertase Subtilisin/Kexin-type 9 Levels.母体肥胖调节脐带血中前蛋白转化酶枯草杆菌蛋白酶/kexin 9型水平。
J Endocr Soc. 2024 Feb 20;8(4):bvae031. doi: 10.1210/jendso/bvae031. eCollection 2024 Feb 19.
8
Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study.循环 PCSK9 作为 2 型糖尿病患者心血管事件的预后生物标志物:来自 16.8 年随访研究的证据。
Cardiovasc Diabetol. 2023 Aug 24;22(1):222. doi: 10.1186/s12933-023-01948-8.
9
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review.蛋白质组学和脂质组学揭示前蛋白转化酶枯草溶菌素9(PCSK9)除降低胆固醇之外的作用:一篇综述
Front Cardiovasc Med. 2023 Jun 12;10:1191303. doi: 10.3389/fcvm.2023.1191303. eCollection 2023.
10
Inhibition of PCSK9 Improves the Development of Pulmonary Arterial Hypertension Via Down-Regulating Notch3 Expression.抑制前蛋白转化酶枯草溶菌素9通过下调Notch3表达改善肺动脉高压的发展。
Cardiovasc Drugs Ther. 2024 Dec;38(6):1223-1234. doi: 10.1007/s10557-023-07458-9. Epub 2023 May 31.